Home » Lupin Files Glumetza ANDA, Notifies Depomed
Lupin Files Glumetza ANDA, Notifies Depomed
Lupin has filed an ANDA for a generic version of Depomed’s Type 2 diabetes medication Glumetza. The company sent Depomed a Paragraph IV certification
notice claiming four patents on the drug are invalid and will not be infringed by Lupin’s manufacturing and selling of Glumetza (metformin HCl),
Depomed says in a statement last week.
Washington Drug Letter
Washington Drug Letter
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May